What Google's Unapproved Substances policy actually restricts, why peptide brands get caught by it, and the compliance playbook that keeps accounts running.
In late 2026, Google quietly consolidated one of the most consequential policies for peptide, research chemical, and specialty supplement advertisers under a single page: Unapproved substances. If you sell BPC-157, TB-500, Melanotan, GLP-1 analogs, or any compound that lives in the grey zone between "supplement" and "pharmaceutical," this is the single policy page that decides whether your Google Ads account survives.
Most peptide brand owners never read it. They find out it exists the day their account gets suspended. This guide breaks down exactly what the policy says, why peptide and research chemical brands get caught by it more than almost any other category, and what a compliant advertising structure actually looks like in practice.
Google's own language is direct. Under this policy, Google does not allow the promotion of certain products "regardless of any claims of legality." That phrase matters — it means the legal status of a compound in your jurisdiction is not, by itself, a defense against a policy violation. Google is enforcing its own commercial standards, not acting as a legal regulator.
The policy names eight specific categories of restricted products:
There's also a standalone carve-out for DHEA products, which are restricted everywhere except campaigns targeting the United States, and a full certification pathway for CBD advertisers — a precedent worth understanding even if you don't sell CBD, covered further down.
For the specific mechanics of how Google decides what belongs on that "unapproved pharmaceuticals and supplements" list, the policy points advertisers to one source: LegitScript. That single sentence is the most important line on the page for anyone in this industry.
Google Ads has no dedicated "peptide" policy category. There's no checkbox for "research compound" or "investigational peptide." Instead, peptide products get evaluated against two overlapping frameworks — the Healthcare and Medicines policy and this Unapproved Substances policy — and LegitScript is the vendor Google uses to populate and maintain the restricted list that both policies reference.
LegitScript's own research shows why this category is under so much scrutiny right now. According to LegitScript's December 2025 data release on the "problematic peptides" market, advertising volume for unapproved peptide products rose 308% between 2023 and 2024, and is up 678% compared to 2022. E-commerce listings for the same category grew 276% over the preceding five years, and social media content promoting these products was up 75% year-over-year. The compounds LegitScript flags most often are the exact ones peptide brands build their businesses around: Melanotan, BPC-157, TB-500, PT-141, and GLP-1 analogs.
In other words, the category you're advertising in is the fastest-growing segment of exactly what Google Ads is trying to restrict. That's not a reason to avoid the channel — it's the reason a generic e-commerce agency will get your account banned and a compliance-first structure will not.
The critical distinction Google draws — and the one most brands miss — is how a product is presented, not just what it is. A peptide sold with laboratory-use framing, no dosing instructions, no condition-specific claims, and clear research-use-only language occupies different territory than the same compound marketed with language like "heals tendons," "treats joint pain," or "burns fat fast." The molecule doesn't change. The ad copy, landing page, and offer structure do — and that's what Google's automated and human reviewers are actually evaluating.
This is the part of the policy that creates the most confusion, because the list itself is non-exhaustive and not published as a static document advertisers can check against in advance. In practice, LegitScript maintains the reference list Google draws from, and it's built around a few consistent markers:
That last point is worth sitting with. Google's policy explicitly restricts "products that have been subject to any government or regulatory action or warning" — and the FDA has issued warning letters to multiple peptide sellers, including brands marketing BPC-157 and similar compounds with therapeutic claims. Once a compound or a specific seller has that history attached to it, Google's systems treat it as higher-risk going forward, even for unrelated advertisers selling the same compound with cleaner positioning. Ingredient-specific restrictions like DHEA, ephedra, and hCG carry their own separate nuances worth understanding on their own — see our deep dive on the overlooked restrictions for the detail.
One detail in the policy is genuinely good news, and almost no peptide brand takes advantage of it: Google does not suspend accounts for this policy without warning. The page states plainly that "a warning will be issued at least 7 days prior to any suspension of your account."
That seven-day window is a compliance opportunity, not a formality. If you're actively monitoring your account status and policy notifications — rather than finding out about a suspension after the fact — you have a full week to either bring the flagged ads into compliance or make the case for an appeal before the account goes dark. Most of the "we got banned overnight with no explanation" stories in this industry are actually "we weren't checking the Ads & assets policy status page and missed the warning." We cover exactly how to build that monitoring habit in our guide to never missing the 7-day warning.
Google gives advertisers exactly two mechanisms once an ad is flagged under this policy, and the difference between them matters strategically.
Editing to comply. This means adjusting the ad, the asset, or the landing page so it no longer triggers the policy — narrowing geographic targeting to locations where the product category is permitted, removing disease or condition claims, or swapping the destination URL to a compliant landing page. Google reviews the edited ad automatically, and status updates appear on the Ads & assets page.
Appealing the decision. This is the right move when you believe the flag was applied in error — for example, if a research-use-only peptide got caught by an automated scan that misread neutral language as a health claim. Appeals go directly through the Google Ads account, and if the review finds the ad genuinely compliant, it can run again.
The mistake most brands make is defaulting to appeal when the actual problem is the landing page. Google's reviewers — automated and human — are increasingly good at cross-referencing ad copy against destination content. An ad that says "for laboratory research use only" linking to a landing page with dosing charts and testimonials about tendon recovery will lose that appeal every time, because the violation isn't in the ad text, it's in the full user journey.
The Unapproved Substances policy dedicates a full section to CBD advertisers, and it's worth understanding even if you don't sell CBD, because it shows how Google handles a restricted category it has decided to allow under controlled conditions.
FDA-approved pharmaceutical CBD advertisers must apply for a specific CBD Ads Certification. Non-pharmaceutical, topical CBD advertisers first need LegitScript certification before they can even apply for the Google certification. Location targeting is limited to California, Colorado, and Puerto Rico, and certain formats (YouTube Masthead, for example) are excluded entirely regardless of certification status.
This matters for peptide brands because it's proof that Google is willing to build a certification pathway for a restricted health category when there's a clear regulatory and verification framework behind it. It's not evidence that a similar pathway exists for peptides today — it doesn't — but it's the model any future peptide-specific certification would likely follow: third-party verification (almost certainly via LegitScript, since it's already the named authority on this exact page), narrow geographic eligibility, and format restrictions. Brands that are already building LegitScript-clean operations now are the ones positioned to move fastest if and when that pathway opens.
Turning this policy into an actual account structure comes down to five things we build into every peptide account we manage:
BPC-157 and GLP-1-adjacent brands deserve a specific note because they sit at the center of LegitScript's most-flagged list. These are also two of the highest-search-volume, highest-commercial-intent categories in the peptide space, which means the pressure to run aggressive, claims-heavy advertising is highest exactly where the policy risk is highest too. Melanotan, TB-500, and PT-141 carry their own distinct compliance notes worth reading — see our compliance guide for those specific compounds, and for GLP-1 specifically, why Google treats it differently from research-only peptides in this comparison.
The brands that scale sustainably in this specific sub-category are the ones that resist the temptation to lead with outcome-based hooks ("recover faster," "lose weight without the injections") and instead build campaigns around research-grade positioning, third-party lab verification, and audience targeting that reaches people already searching with research intent rather than consumer intent. It's a narrower top-of-funnel, but it's the version of the account that survives a policy review.
No. The published policy text doesn't use the word "peptide." It restricts categories — unapproved pharmaceuticals and supplements, products implying prescription-drug equivalence, products tied to regulatory action — that peptide products routinely fall into based on how LegitScript classifies them, not because of a peptide-specific carve-out.
Not on its own. A disclaimer helps, but Google's review process looks at the entire user journey — ad copy, landing page, product titles, even visible customer reviews. A disclaimer that contradicts the rest of the funnel won't hold up.
No. Per the policy, Google issues a warning at least seven days before any account suspension tied to this policy, which gives you a real window to fix the issue or appeal.
Yes, brands do it successfully, but it requires research-grade positioning across the entire funnel, careful geo-targeting, and Merchant Center feeds that match the ad account's compliance posture — not a single compliant ad running to a non-compliant landing page.
Google references LegitScript as its authority on unapproved pharmaceuticals and supplements. Our explainer on how LegitScript's monitoring list actually works covers what it tracks and how brands end up on it.
Peptide advertising isn't unwinnable on Google — it's just unforgiving of guesswork. The brands that treat this policy as a design constraint for their entire funnel, not just their ad copy, are the ones still running campaigns a year from now.
See how a peptide brand with prior policy history was rebuilt into a compliant, scaling account.
Get a free 30-minute audit of your Google Ads or Meta Ads account. We’ll review compliance, structure, and growth opportunities — no strings attached.
Book a Free Audit